Guidance Up Six Points, Stock Down Six Percent: The Pill Works, US Wegovy Injectable Falls 22%

Results vs. Consensus

Novo Nordisk reported before the European open on 4 August 2026 and hosted its call at 13:00 CEST, 7:00 AM ET the same day, ahead of the US open. As in Q1, the quarter has to be read on two bases. Unlike Q1, the distortion runs the other way: there was no 340B provision reversal in Q2 2026, but there was one of DKK 2,649M in Q2 2025, so the reported comparison understates the business while last year's base is inflated. Reported operating profit also carries DKK 6,328M of non-cash impairments on intangible pipeline assets. The adjusted basis, which strips the prior-year reversal and this year's impairments, is the one the company guides against and the one used throughout below.

Q2 2026 Scorecard (adjusted basis, DKK)

A note on the consensus set. The same three-basis problem that muddied Q1 is still live. The DKK 28,740M figure is the company-compiled analyst poll for adjusted operating profit, carried by two independent outlets, and it is the comparison management is judged on. A separate set of USD per-ADR forecasts circulated alongside it, one of which produced a headline revenue beat of more than a tenth by comparing an adjusted-basis actual against a lower forecast base. Novo's adjusted sales grew 7% at constant currency in the quarter. There is no basis on which revenue beat by a tenth. The one genuinely useful second datapoint is the Wegovy pill line, where the polled figure of DKK 3.27bn was missed by a fraction, and that small miss on the single most-watched line in the model did more to the tape than the 16% operating-profit beat did.

Year-over-Year Comparison

The reported column is again the one to discard, and this time it is unflattering rather than flattering: operating profit down 19% in kroner, net profit down 21%, diluted earnings per ADR down 20%. Two items produce all of that. Last year's quarter carried a DKK 2,649M rebate reversal that will not repeat, and this year's carries DKK 6,328M of non-cash impairments on intangible pipeline assets sitting in the research and development line. Strip both and the business grew adjusted operating profit 11% at constant currency on 7% sales growth, with 100bps of margin expansion. Anyone screening on reported trailing figures now has two consecutive quarters of noise pointing in opposite directions.

The cost of goods sold line deserves separate attention because it is the largest single mover in the table. It rose 33% in kroner on 6% sales growth, which on its face is a collapse in unit economics. Roughly DKK 3bn of it is a one-time charge for right-sizing manufacturing capacity agreements, which the company disclosed but did not exclude from the adjusted figures. That charge alone is worth roughly 380bps of the 450bps adjusted gross-margin decline.

Sequential Comparison

The sequential view is the mirror image of last quarter's. In Q1 sales fell 11.5% and operating profit rose 3.5%. In Q2 sales rose 12.0% and operating profit rose 1.6%. Both quarters produced roughly DKK 33bn of adjusted operating profit on very different revenue bases, which tells you the Q1 margin was the anomaly and this one is closer to the run rate. The 440bps of sequential margin compression is exactly what we flagged in April: the Q1 legal-provision release did not repeat, the sales and distribution ratio stepped up 190bps toward the guided level, and the manufacturing charge landed in this quarter's cost line. Adjusted earnings per share fell 6.8% sequentially on 12% higher sales, which is the arithmetic of that compression plus a swing in financial items from a DKK 2,554M gain in Q1 to a DKK 186M loss here.

First-Half View

Six months in, the business is flat. Adjusted sales up 2% at constant currency, adjusted operating profit up 2%, adjusted earnings per share up 1%. That is a better starting point than the guidance implied in February and it is the reason the outlook moved. It is also a long way from the growth company the multiple used to be struck against, and the halves are not symmetrical: management has now named the two items that make the second half harder.

Quality of Beat/Miss

• Revenue: Adequate, with a caveat that matters for the run rate. The 7% constant-currency growth is genuine volume growth in GLP-1 across both operating units, but roughly three points of it is a prior-period rebate true-up that reverses nothing and repeats nothing. Underlying growth of roughly 4% is still the best quarter Novo has printed in over a year and still a fraction of its market's volume expansion. There is no acquisition contribution and no channel-fill benefit of consequence in the US pill line this quarter, which is an improvement on Q1 where two-fifths of the pill number was inventory build.
• Margins: Better than the headline. Adjusted gross margin of 78.2% against 82.7% looks like a 450bps structural erosion; roughly 380bps of it is the manufacturing right-sizing charge. Ex that charge the gross margin is near 82.0%, a decline of roughly 70bps on lower realised prices and negative currency, partly offset by GLP-1 mix and productivity. Below the gross line the operating leverage is real: sales and distribution down 13% at constant currency on 7% higher sales, and research and development down 2%. Adjusted operating margin expanded 100bps year on year despite the charge.
• EPS: Adjusted diluted EPS of DKK 6.18 rose 5% against 11% constant-currency operating-profit growth, so below-the-line items were a drag. Financial items swung to a DKK 186M loss from a DKK 356M gain, the effective tax rate was near-flat at 21.9% against 21.6%, and the diluted share count fell 0.2% to 4,435.8 million. The DKK 5.9bn of buybacks executed in the first half against DKK 35.3bn of dividends is not moving the per-share line in any meaningful way.

Segment Performance

Adjusted Sales by Geography

The swing from Q1 is the US line going from -11% to +4% at constant currency, and roughly five of those fifteen points are the rebate true-up rather than trading. International Operations contributed 65% of group growth on 10% constant-currency expansion, led by EUCAN. Two regions inverted: Emerging Markets from -18% to +5% and Region China from -10% to +13%, both against soft Q2 2025 comparatives, while APAC went the other way, from +22% to -6%.

Adjusted Sales by Therapy Area

Diabetes stopped shrinking. That is the single largest change in the quarter's arithmetic. In Q1 the segment fell 12% at constant currency on a DKK 44.9bn base and swamped a 22% obesity gain on a DKK 20.9bn base. In Q2 diabetes grew 3% on a DKK 50.4bn base, so the obesity growth finally flows through to the group line instead of being absorbed. How much of the diabetes turn is durable is the open question: US GLP-1 diabetes grew 3% at constant currency and management attributed that directly to the rebate adjustments, with volumes described as slightly lower.

Obesity Care Versus Its Own Market

This is the table that decided the rating in April and it is the table that decides it again. It is the company's own, sourced to IQVIA moving annual totals at May 2026.

One region closed the gap and it is the smallest: Emerging Markets, at 45% growth against a 55% market, is the first geography in two quarters where Novo grew at a rate within hailing distance of its category. Everywhere else the wedge persisted or widened. The US is the one that matters, and it went the wrong way in both directions at once, with Novo decelerating from 9% to 4% while the market accelerated from 85% to 87%.

US Operations

US obesity care sales of DKK 12,824M grew 4% at constant currency. Inside that, Wegovy injectable fell 22% at constant currency to DKK 9,636M and Wegovy pill contributed DKK 3,141M. The pill is no longer merely flattering the segment as it did in Q1; it is now the only thing keeping it positive by a wide margin, and it is doing so at a materially lower price point than the product it is displacing.

Management was unambiguous that this is a price story rather than a demand story, and the mechanism is a channel shift the company is deliberately driving.

"Right now for Wegovy injectable in the U.S., self-pay is to the tune of 35% of total Wegovy injectable compared to a year ago, where we were around the 10%-15% range. It's at a different price point, but it's a good way to unlock volume."
— Karsten Munk Knudsen, CFO

The disclosed prescription data corroborates it. For the week ending 17 July, US injectable Wegovy ran at around 310,000 weekly prescriptions, of which around 120,000 were filled self-pay. A franchise that has moved from roughly one script in eight at cash prices to roughly two in five, while cutting nothing on list, will print falling revenue on rising volume for as long as the mix keeps shifting.

Assessment: A 22% constant-currency decline in the flagship US product, in a quarter when the US branded obesity market grew volumes 87%, is the single most important number in this report. The self-pay explanation is credible and management's framing that cash pricing "unlocks volume" is strategically right. It is also an admission that the US obesity franchise is now growing units into a falling revenue base, and the pill is accelerating that shift rather than arresting it. Nothing in this quarter changes the conclusion we reached in April: the volume engine works and the price engine is running in reverse faster.

International Operations

International obesity grew 37% at constant currency against a 71% market. That is the same ratio of company growth to market growth as Q1 delivered, which is a genuine if unglamorous result: the under-growth stopped getting worse outside the US. EUCAN at 52% against an 82% market did the heavy lifting, with Wegovy injectable in EUCAN up 63% at constant currency on the 7.2 mg single-dose pen and the Ozempic 2.0 mg rollout. Region China rebounded 104% off the list-price-reset base that produced Q1's 37% decline. APAC was the outlier at -9%, against a market up 53%.

"Novo Nordisk continues to be volume market leader outside the U.S. with around 58% GLP-1 volume market share. While our market share has been declining over recent quarters, we see encouraging trends as our share of growth continues to stabilize."
— Emil Kongshøj Larsen, EVP International Operations

The figure is not directly comparable to the roughly 55% injectable GLP-1 volume share disclosed at Q1, because the basis has broadened from injectable to all GLP-1 and the pill has since launched in two international markets. Read as a trend statement rather than a level, it says the same thing as last quarter with slightly more confidence behind it.

Assessment: International is the half of the business that is working, and the UK pill launch gives it a second engine. The caution is that the loss-of-exclusivity clock and the share recovery are running against each other in the same geographies, and management has now said the exclusivity impact is back-end loaded into the half that has already begun. A 37% growth rate here is not the run rate to carry forward.

Diabetes Care

Diabetes care sales of DKK 50,429M grew 3% at constant currency, with US diabetes up 4% and international diabetes up 3%. Ozempic grew 5% globally, its first positive quarter in the period we have covered, with US Ozempic up 2% on rebate adjustments against lower realised prices and lower volumes, and international Ozempic up 10% on EUCAN volumes. Rybelsus, now re-branded Ozempic pill, fell 4% globally but grew 7% in the US on relaunch-related wholesaler pipeline fill. Insulin grew 6% globally and 15% in the US, which management attributed to rebate timing against a declining market and continued share loss.

"Ozempic® continues to see solid sales momentum, with sales growth of 10% in the second quarter. This is partially driven by Ozempic® 2.0 milligram, which is now launched in around 10 countries with good uptake, coupled with strong overall Ozempic® performance across key European markets."
— Emil Kongshøj Larsen, EVP International Operations

The US GLP-1 diabetes market grew volumes 12% on a moving-annual-total basis while Novo's US GLP-1 diabetes sales grew 3%; the international market grew 40% while Novo's international GLP-1 diabetes sales were flat. The under-growth pattern is intact in diabetes even as the absolute direction turned positive.

Assessment: The diabetes turn is what let the group print 7%, and roughly half of it is not trading. Strip the Ozempic and insulin rebate true-ups, worth roughly DKK 2bn between them, and Diabetes care is close to flat rather than up 3%. Management gave no indication these adjustments recur. Treat Q2 diabetes as flat and the group's underlying growth as roughly 4%.

Rare Disease

Rare disease sales of DKK 4,907M grew 6% at constant currency, with US rare disease up 12% on Norditropin and Sogroya volumes after the Q1 wholesaler de-stocking, and international up 1%. The segment reported an operating loss of DKK 1,295M against a DKK 518M profit a year ago, which reads as a collapse and is not one.

The announcement does not split the DKK 6,328M impairment charge by segment. It does identify monlunabant, an obesity asset, at DKK 4.0bn of the total. Allocating that DKK 4.0bn to Obesity and Diabetes care and the residual DKK 2,328M to Rare disease reconciles both segments to the group adjusted operating profit exactly, and on that basis Rare disease earned roughly DKK 1.0bn of adjusted operating profit at about a 21% margin against 10.5% a year ago. That allocation is a reconstruction rather than a disclosure. What is not in doubt is that a segment growing 6% at constant currency with rare endocrine disorders up 24% did not swing to a loss on trading.

Assessment: Rare disease is quietly having a good year and the reported segment line is now actively misleading in the opposite direction from Q1, where the 340B allocation inflated it. Etavopivat remains on track for US and EU submission in the fourth quarter, and the Sogroya label expansions in the EU and Japan broaden a franchise that was static for years. Still six percent of sales, still immaterial to 2026, still the cleanest part of the story.

Commercial KPIs

Key Topics & Management Commentary

Overall Management Tone: Assured on the commercial story and conspicuously careful everywhere else, which is a shift from the uniformly confident posture of the Q1 call. Management led with launch metrics and a guidance raise, then spent the middle of the call absorbing questions on a failed cardiovascular trial, a terminated obesity asset, a missed endpoint against the category leader, and a 22% decline in the flagship US product, answering each without deflection but also without new numbers. The one place the register genuinely changed was the closing remarks, where the chief executive volunteered that the year is not over and named the second half as harder, language absent from April.

1. The Guidance Raise Is Real De-Risking, and It Banks the First Half Rather Than Extrapolating It

Both ends of both ranges moved up six percentage points, to 0% through -6% at constant currency from -4% through -12%. That is not the parallel shift we criticised in April; the band narrowed from eight points to six, and the floor moved as far as the ceiling. Free cash flow guidance rose DKK 9bn to DKK 45-55bn. Measured against the opening February guide of -5% through -13%, the floor has now travelled seven points in six months.

What the raise does not do is imply an accelerating second half. Applying the guided range to a 2025 adjusted sales base of DKK 306.4bn and subtracting the first half's DKK 154.7bn at constant currency puts implied second-half growth at roughly -1.5% to -13.5%, midpoint near -7.5%, against the first half's +2%. The chief financial officer gave the bridge himself, and it is arithmetic rather than judgement.

"In terms of outlook, the balance of year logic you're after, the simple version is that we take our current run rate, where we deliver 2% growth in the first half and continue with that run rate. You factor in two factors, one being loss of exclusivity for Sema in a few markets, Canada and Brazil mainly, which we see happening here predominantly starting in the second half. You take into account the favorable gross to net effects we had in Q3 and Q4 last year of combined DKK 5 billion."
— Karsten Munk Knudsen, CFO

The DKK 5bn of prior-year gross-to-net benefit is the more useful of the two disclosures because it is dated, quantified, and certain. On a second-half 2025 adjusted sales base of DKK 154.1bn it is worth roughly 3.2 points of growth on its own, before any loss-of-exclusivity impact.

Assessment: This is the first Novo guidance action in our coverage that carries information rather than posture. A six-point lift with a narrowed band, after a first half that delivered, is management telling you the low case has been retired. It is also worth noticing what the raise is made of: the first half beat and the second half was not raised with it. The company has upgraded the year it has already largely banked.

2. Two One-Offs, Pointing in Opposite Directions

Neither of the quarter's two material non-recurring items appears in the guidance table and neither is excluded from the adjusted figures. Both were quantified on the call. The first is a favourable prior-period gross-to-net rebate true-up on the revenue line.

Q: "Just on the rebase adjustments, could you quantify where they sit across the portfolio, particularly Ozempic®?"
— Graham Parry, Citi

A: "In terms of the gross to net adjustments, the 2 billion DKK that we've highlighted, the strongest proportion of that is Ozempic®. About three quarters of the impact is Ozempic® gross to net, and then the balance is insulin."
— Jamey Millar, EVP US Operations

The second is a cost, and it is larger.

"The adjusted gross margin was realized at 78.2% compared to 82.7% in Q2 2025, reflecting lower realized prices, one-time cost of around DKK 3 billion related to right sizing of manufacturing capacity agreements, as well as a negative currency impact."
— Karsten Munk Knudsen, CFO

Netting them: adjusted sales growth at constant currency drops from 7.0% to roughly 4.3% without the rebate, the adjusted gross margin rises from 78.2% to roughly 82.0% without the manufacturing charge, and underlying adjusted operating profit is roughly DKK 34.4bn against DKK 33,389M printed. The revenue is lower quality than it reads and the profit is higher quality than it reads.

Assessment: The market appears to have priced the first of these and ignored the second, which is the wrong way round for anyone building a 2027 model. A rebate true-up is a timing item that inflates a single quarter's growth rate and leaves the base unchanged; a manufacturing right-sizing charge is a real cash cost that will not recur and depresses a margin that is otherwise close to flat. On the numbers, the operating performance underneath this print is the best Novo has produced since we picked up coverage.

3. Wegovy Pill Goes Global, and the UK Is the Datapoint of the Quarter

Six months after launch the pill has more than five million US prescriptions, around 267,000 weekly as of 17 July, and roughly 90% of the US oral obesity medication market despite a competitor launching in early April. Roughly 80% of users remain GLP-1 treatment-naive. The company now reports around 1.5 million people worldwide on the product.

The more informative development is what happened when the pill left the US. It launched in the UAE in June and the UK in early July, and the UK response was outside anything the US launch produced on a comparable timescale.

Q: "On the ex-U.S. Wegovy pill trajectory, U.K., you said 300,000 patients in the first three weeks or so since launch. That compares to 48,000 for the U.S. How comparable are the launch trajectories for the U.S. versus ex-U.S. markets?"
— James Quigley, Goldman Sachs

A: "Mind you, almost three out of 10 obesity patients on a once weekly GLP-1 and IO live in the U.K., but it's still only 1.6 million patients being treated out of 20. The room for market expansion is tremendous in the U.K. As you rightly point out, there was a pent-up demand. A lot of patients have been on the sidelines even more than we could have hoped for, it just goes to show that the injection barrier is very real and this uptake is of course tremendous."
— Emil Kongshøj Larsen, EVP International Operations

Novo's UK obesity market share on IQVIA sell-in went from roughly 30% before the launch to 45% in July. Germany follows in September, a market management described as already a third telehealth by channel.

Assessment: The pill is doing exactly what the bull case requires: expanding the treated population rather than cannibalising the injection. Three hundred thousand UK starts in three weeks against a pre-launch national treated base of 1.6 million is a nineteen percent expansion of a country's obesity treatment market by one product in under a month. The catch is the same one as in the US. Every one of those patients arrives at an oral price point, and the international rollout is therefore the mechanism by which the lower price level propagates from the US to the rest of the world faster than we assumed in April.

4. US Wegovy Injectable Fell 22%, and an Analyst Sized the Wedge Publicly

The flagship product's US sales declined 22% at constant currency in a quarter when its own market grew volumes 87%. Management's answer was that nothing new is happening on price, only more of what was guided in February.

Q: "Wegovy U.S. performance, minus 22% in constant exchange rates. Jamey, could you try to give us some info on the dynamics you're seeing here in Q2 for Wegovy in the U.S. market... Should we worry that there's increasing pricing pressure seen or maybe light pricing pressure on new channels at lower prices coming on stream?"
— Carsten Lønborg Madsen, Danske Bank

A: "I think as we highlighted at the beginning of the year, we were expecting volume growth but continued price pressure, and that's what we've seen. I think you answered the question almost in your question. We did see volume growth with Wegovy injectable, but that was offset by lower realized prices than we anticipated. No new price dynamic impacting it. It's the price dynamic that we started the year with."
— Jamey Millar, EVP US Operations

"Lower realized prices than we anticipated" is doing a great deal of work in a sentence that otherwise says nothing has changed. Later in the call the wedge was quantified from outside: a negative price-mix effect of roughly 57%, against roughly 40% in Q1. That estimate was put to management directly and drew no correction, only a note that the quarter-to-quarter mix fluctuates.

Assessment: The two halves of the answer do not sit together comfortably. If the price dynamic is unchanged from the one guided in February, prices should not be lower than anticipated. What is really happening is a mix shift the company is choosing: self-pay has gone from roughly one-eighth to roughly 35% of US injectable Wegovy in twelve months because that is where the incremental volume is. That is a defensible strategy and a deteriorating revenue line, and the two are the same decision.

5. The US Share Gap Widened, and It Is the One Test We Set in April

At initiation we wrote that a quarter in which US obesity revenue growth closed a meaningful part of the gap to US branded obesity market volume growth was the single condition for moving toward Outperform. The gap in Q1 was 9% against 85%. In Q2 it is 4% against 87%. On the company's own table the gap widened by seven points.

Management offered a different cut of the same market on the call, framing the growth as narrower.

"The branded obesity medication market continues to expand in Q2 2026, growing volumes at around 70% compared to Q2 2025. The Wegovy franchise is playing a major role in this expansion, where the franchise continues to be the leader measured on NBRX with a market share of around 60% during the month of July."
— Jamey Millar, EVP US Operations

Take the more favourable of the two figures and Novo's US obesity revenue grew 4% into a market whose volumes grew 70%. And the new-to-brand share, the leading indicator we identified in April as the most plausible route to share stabilisation, went from around 65% to around 60%.

Assessment: This is the quarter that was supposed to start closing the gap and it opened it further, while the leading indicator that was supposed to predict the close moved five points the wrong way. Realised price erosion explains the direction of the wedge and cannot explain a gap this wide in the same quarter the company launched the category's best-selling new product and a higher-efficacy injectable. The bear pillar we opened at initiation is not just intact, it strengthened.

6. ZEUS Failed, and It Was the Cardiovascular Leg of the Story

Announced in late July and confirmed in the quarter's disclosure, the ZEUS phase 3 cardiovascular outcomes trial of ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation did not meet its primary endpoint. More than 6,300 patients were randomised. The mechanism worked and the outcome did not.

"While ziltivekimab showed target engagement and inhibition of the IL-6 pathway as reflected by expected reduction in free IL-6 and hsCRP respectively, this does not translate into MACE reductions with a hazard ratio of 0.99."
— Martin Holst Lange, EVP Research and Development and Chief Scientific Officer

A hazard ratio of 0.99 is not a near-miss; it is an absence of effect. All-cause mortality was likewise 0.99, and a higher proportion of treated patients had serious infections, consistent with IL-6 inhibition. The ARTEMIS and HERMES outcomes trials of the same molecule in acute myocardial infarction and heart failure with preserved ejection fraction continue, with results expected in the first half of 2027. The company flagged that the outcome may produce a further non-cash impairment charge in the third quarter.

Assessment: Ziltivekimab was one of four assets underpinning the pipeline optionality pillar we opened at initiation, and it was the one that gave Novo a leg outside the incretin franchise. Management's position that the inflammation hypothesis is unproven rather than disproven is scientifically reasonable and financially irrelevant for 2027 and 2028. The stock fell 8.8% on the readout day, which is the market pricing the option to zero. We agree with that pricing and note the two continuing trials are now lottery tickets rather than a programme.

7. CagriSema Missed Half of a Dual Primary Endpoint Against the Category Leader

REIMAGINE 4 was an open-label 68-week head-to-head of CagriSema 2.4/2.4 mg against tirzepatide 15 mg in type 2 diabetes, on the dual primary endpoints of weight and HbA1c. CagriSema achieved 15.2% weight loss against 15.8%, and a 1.9 percentage-point HbA1c reduction against 2.2. It met non-inferiority on the first and did not meet it on the second.

"For the dual primary endpoint, CagriSema demonstrated non-inferiority versus tirzepatide for weight reduction, but not for HbA1c reduction."
— Martin Holst Lange, EVP Research and Development and Chief Scientific Officer

Pressed on what that means for positioning in a therapy area where glycaemic control is the endpoint physicians prescribe against, the response widened the frame to the whole molecule rather than the trial.

"I'll just remind you that across the CagriSema two diabetes trials, we've seen A1c lowering between -1.8% and 2.3%, so very, very strong glycaemic control. In the REIMAGINE 4, it was 1.9%. At the same time, we've seen an almost unprecedented 15% weight loss."
— Martin Holst Lange, EVP Research and Development and Chief Scientific Officer

The US regulatory decision for CagriSema in obesity is still expected at the end of 2026 with a potential 2027 launch, and REIMAGINE 4 is a diabetes trial, so the obesity filing is unaffected on its face. The lower-dose REDEFINE 9 trial completed successfully and a high-dose REDEFINE phase 3 has started, reading out in the first half of 2028.

Assessment: The trial that was supposed to establish CagriSema as at least equivalent to the category leader established that it is not, on the endpoint that matters most in its comparator's home indication. The commercial consequence lands in diabetes, not obesity, so the year-end obesity decision is undisturbed. The thesis consequence is larger: CagriSema was the next-generation asset expected to carry the franchise past semaglutide's exclusivity, and it has now delivered a disappointing headline in December 2024's REDEFINE 1 and a missed endpoint here. Two data disappointments in eighteen months on the same asset is a pattern.

8. Monlunabant Terminated and DKK 6.3bn Written Off

Novo terminated development of monlunabant "due to portfolio considerations" and took DKK 6,328M of non-cash impairments on intangible pipeline assets, of which DKK 4.0bn relates to that asset. The charge sits in the reported research and development line, taking it to 22.7% of sales against an adjusted 14.6%.

The termination did not come up in the question-and-answer session at all. Between monlunabant, ziltivekimab and the REIMAGINE 4 endpoint miss, the quarter removed one asset from the pipeline, neutralised a second, and downgraded the competitive claim of a third, and the aggregate of analyst questions specifically on pipeline attrition was one, asked last, in the final minutes of the call.

Assessment: The DKK 4.0bn is non-cash and the accounting is clean. What is worth marking is the cadence. Novo is now writing off obesity assets rather than adding them, which is a different position from the one it occupied when we initiated coverage in May on a pipeline-optionality pillar. The company has a capital markets day in September; that will be the forum where this either gets a coherent frame or does not.

9. The Cost Base Is Ahead of Plan and the Spend Is Still Coming

Sales and distribution costs fell 13% at constant currency for a second consecutive quarter, to 19.1% of adjusted sales against 23.6% a year ago. Headcount fell again.

"Through our disciplined cost-based approach, we are now ahead of plan to deliver the DKK 8 billion of savings from the company-wide transformation announced back in the third quarter of 2025, which are being reinvested into growth opportunities. At the end of the second quarter, the number of full-time employees was around 66,700, which is a decrease of almost 12,000 employees corresponding to roughly a 15% decline compared to 12 months ago."
— Karsten Munk Knudsen, CFO

Against that, the two commitments we were tracking from the Q1 call are only partly delivered. The sales and distribution ratio was guided to the "low 20s" for the full year against Q1's 17.2%; it printed 19.1% in Q2 and 18.2% for the half, which requires roughly 22% to 23% across the remaining two quarters. The research ratio was guided higher from Q1's 14.7%; it printed 14.6%, effectively flat. The disclosure now says only that research spend and promotional activities are expected to increase in the second half, without a ratio attached.

Assessment: The transformation is delivering more than promised and the workforce reduction is now roughly 15% in a year, which is a genuine structural change to the cost base rather than a phasing story. But the spend management said was coming in April still has not arrived, and dropping the numerical ratio guide makes it harder to hold them to it. Either the second half carries a step-up of several billion kroner across both lines, in which case the margin falls sharply from here, or the low-20s guide was conservative and the cost base is permanently lower. Management has stopped saying which.

10. Loss of Exclusivity Is Live, and Back-End Loaded Into the Half That Has Started

The semaglutide patent cliff moved from prospect to fact during the quarter. Canada is the first market where it shows in the numbers, with lower realised prices against broadly stable Novo volumes, and Sandoz filed in the Unified Patent Court in June seeking revocation of the unitary patent covering the 1 mg diabetes dose across eighteen EU countries.

"Recently, we saw the first generic entries in the early LOE markets. While modest so far, the LOE impact is expected to be back-end loaded in the second half of 2026. Although it is early days, we generally see the market expanding in the early LOE countries, mainly driven by more products being available at lower prices and significant promotional investments by new entrants."
— Emil Kongshøj Larsen, EVP International Operations

The observation that generic entry expands the market is genuinely interesting and consistent with what the pill is doing at a lower price point in the US. It is also a statement about units rather than revenue.

Assessment: The company's framing has shifted in one quarter from "guidance assumes a low-single-digit group impact" to a named driver of second-half deceleration. That is not a deterioration in the facts, it is the facts arriving on schedule, and the guidance raise already absorbs it. The forward point is that the impact annualises into 2027, which the chief financial officer confirmed and which sits alongside the January list-price reset in the same year.

11. Free Cash Flow: the First Half Already Exceeds the Full-Year Midpoint

First-half free cash flow was DKK 55,297M, up 44%, driven by the phasing of operating expenses and the timing of US rebate and tax payments alongside lower capital expenditure. The full-year guidance, raised this quarter, is DKK 45-55bn.

Those two figures cannot both be met by a positive second half. The guide implies second-half free cash flow of roughly negative DKK 10.3bn to negative DKK 0.3bn. No question was asked about this on the call.

Assessment: The headline is a DKK 9bn free cash flow raise; the substance is that essentially the entire year's cash generation has already happened and the timing benefits reverse. This is not a problem, it is a working-capital pattern in a business whose US gross-to-net cycle runs a long payment tail, and the raise is still a raise. But a reader who takes DKK 55bn of first-half free cash flow as a run rate is off by a factor of two on the year, and management left that uncorrected in a quarter when it drew no questions.

12. Medicare Bridge Started, the 2027 Price Reset Still Has No Bridge

The Medicare Part D obesity pilot began on 1 July and covers a majority of beneficiaries. Early read is positive and deliberately unquantified.

Q: "Could I push you further on the Medicare Bridge program? Your competitor's been more bullish on the volume inflection potential. I think Novo's been trying to keep expectations down, but just what you're seeing at the moment, and just to clarify or to confirm that the current guidance still bakes in conservative assumptions on the Bridge program volume uplift."
— Peter Verdult, BNP Paribas

A: "In terms of absolute volume of patients making it through the eligibility screen and the PA criteria and gaining treatment through a paid prescription claim, we're very pleased with the volume so far. Whether or not that is durable and sustainable is yet to be seen. We'll be monitoring that as we continue and progress, we will be focused on gaining our fair share of the prescriptions as well as we move forward."
— Jamey Millar, EVP US Operations

Separately, the 1 January 2027 reduction in wholesale acquisition cost to USD 675 across Wegovy injection 2.4 mg and 7.2 mg, Wegovy tablets, Ozempic injection and Ozempic pill, approximately 50% on Wegovy and 35% on Ozempic, appears in this quarter's disclosure in the same paragraph, with the same single sentence on financial effect, as it did in the last one. It drew no question.

Assessment: Bridge is the volume offset the 2027 price reset requires, and one quarter on from the reset's announcement the company has a pilot running with encouraging early data and still no published bridge between the two. That is the largest single modelling variable in the name entering its second consecutive quarter unquantified, now with the reset five months nearer. The chief financial officer deferred 2027 to February, which means the gap does not close before the fourth-quarter results.

Guidance & Outlook

The shape of this revision is what separates it from the last one. In May both ends moved a single point and the band stayed eight points wide, which we read at the time as a refusal to de-risk. In August both ends moved six points and the band narrowed to six. Management is no longer holding open a double-digit decline scenario. The free cash flow raise of DKK 9bn is the largest single guidance change of the year and, as set out above, is essentially a first-half phenomenon.

The footnote persists that on a non-adjusted basis the 2026 midpoints would be +5% on sales and +12% on operating profit, which is the 340B reversal talking. That Novo has now footnoted the same reconciliation three announcements running is a fair signal of how much reported-versus-adjusted confusion it expects to live with for the rest of the year.

Implied second-half ramp: A 2025 adjusted sales base of DKK 306.4bn against the guided range puts full-year 2026 adjusted sales at DKK 288.0bn to DKK 306.4bn at constant currency. The first half delivered DKK 154.7bn on the same basis, leaving DKK 133.4bn to DKK 151.8bn for the second half against DKK 154.1bn a year ago. That is second-half growth of roughly -1.5% to -13.5% at constant currency, midpoint near -7.5%, against a first half that grew 2%. An analyst put the implied figure at "around 5% or so negative growth" on the call and management did not dispute the framing. Two named items account for most of the deceleration: the DKK 5bn of favourable second-half 2025 gross-to-net effects that do not repeat, worth roughly 3.2 points on their own, and the back-end-loaded loss of exclusivity in Canada and Brazil.

Street at: Consensus entering the print sat against a guidance band that has now moved six points, so the mechanical revision upward is larger than for any quarter this year. The place where the Street is most likely to be wrong is the second-half operating margin. The first half delivered 44.6% adjusted; the full-year guide combined with the implied second-half sales decline, and with the company's own statement that research spend and promotional activity both rise in the second half, points materially lower. Carrying 44.6% forward is carrying a number the guide has already contradicted.

Guidance style: Still conservative in level, now credible in shape. This management team has raised twice in six months, each time on delivered results rather than expected ones, and has narrowed rather than widened when it had the evidence. That is the behaviour of a team rebuilding a forecasting reputation, and it is being rewarded on the metric that matters least to the share price. The one item that has moved consistently the wrong way is financial items, guided from a DKK 2.3bn gain in February to a DKK 1.1bn loss now, a DKK 3.4bn deterioration inside a single year that reduces earnings without touching the guided operating lines.

Analyst Q&A Highlights

The Shape of the Second Half, and What Carries Into 2027

The first question of the call went straight to the arithmetic gap between a first half that grew and a full-year guide that declines, and asked which of the second-half headwinds also persist into next year. The answer was unusually specific, naming both items and separating the one that annualises from the one that does not.

Q: "On the guidance for second half implies around 5% or so negative growth. Can you talk to the dynamics and the headwinds that you have there? Which of those headwinds could potentially also move forward into 2027 and impact growth there?"
— James Quigley, Goldman Sachs

A: "In terms of outlook, the balance of year logic you're after, the simple version is that we take our current run rate, where we deliver 2% growth in the first half and continue with that run rate. You factor in two factors, one being loss of exclusivity for Sema in a few markets, Canada and Brazil mainly, which we see happening here predominantly starting in the second half. You take into account the favorable gross to net effects we had in Q3 and Q4 last year of combined DKK 5 billion. If you take that carry forward, of course, the comparative effect, we don't carry forward into next year, whilst the loss of exclusivity impact will annualize into next year."
— Karsten Munk Knudsen, CFO

Assessment: The most useful answer of the call and a marked improvement on April, when a comparable question about the guidance floor got a lecture on how to interpret confidence signals. Naming DKK 5bn and separating the comparative from the structural is exactly the disclosure a modeller needs. The implication is also clear and unflattering: the second half decelerates by roughly nine points from the first, more than half of it a comparative that reverses, and the remainder is permanent.

Whether the UK Launch Reads Across to Other International Markets

Three hundred thousand patient starts in three weeks against forty-eight thousand in the equivalent US window invited the obvious question of how much of that is a UK-specific backlog and how much is a template. The answer conceded the pent-up demand explicitly and then argued that the next market is different in structure but similar in unmet need.

Q: "Secondly, on the ex-U.S. Wegovy pill trajectory, U.K., you said 300,000 patients in the first three weeks or so since launch. That compares to 48,000 for the U.S. How comparable are the launch trajectories for the U.S. versus ex-U.S. markets? What have you seen in terms of waiting lists, and things like that for the U.K.? Are there any similar metrics or expectations you have for the Germany launch that you've seen with the U.K. launch as well?"
— James Quigley, Goldman Sachs

A: "In terms of the read across to Germany, it is quite a different market, Germany is also a market that versus a year ago, is now driven by telehealth. More than half of the growth and a third of the market is already sold through telehealth channels, there is an increasing awareness in the population and an even larger unmet need because treatment rates are lower. We start from a different base, we'll use a lot of the same tactics in Germany, we are bullish on the uptake there as well."
— Emil Kongshøj Larsen, EVP International Operations

Assessment: Honest on the UK being a release of stored demand rather than a repeatable weekly run rate, which matters because a first-three-weeks number from a backlog does not annualise. The Germany framing is credible on unmet need and quiet on price, which is the variable that determines whether these launches add revenue or units. A market already a third telehealth is a market where the self-pay price point sets the realised price from day one.

The 22% Decline in the Flagship US Product

The sharpest exchange of the call, and the one whose answer contains its own contradiction. The question offered management two explanations and asked it to choose; the response took neither cleanly, asserting that no new pricing dynamic exists while conceding that realised prices came in below the company's own expectation.

Q: "Wegovy U.S. performance, minus 22% in constant exchange rates. Jamey, could you try to give us some info on the dynamics you're seeing here in Q2 for Wegovy in the U.S. market, and also maybe help us understand a little bit the very last discrepancy versus Q1 and also the prescription data that we can see which points to growth, of course, but then there's a pricing component. Should we worry that there's increasing pricing pressure seen or maybe light pricing pressure on new channels at lower prices coming on stream?"
— Carsten Lønborg Madsen, Danske Bank

A: "We did see volume growth with Wegovy injectable, but that was offset by lower realized prices than we anticipated. No new price dynamic impacting it. It's the price dynamic that we started the year with."
— Jamey Millar, EVP US Operations

Assessment: Those two sentences cannot both be fully true. Prices that come in lower than anticipated are, by definition, a dynamic that differs from the one planned for. The reconciliation offered afterwards, that self-pay has gone from 10-15% to roughly 35% of US injectable Wegovy in a year, is the real answer and is more useful than the denial preceding it. It also frames the risk correctly: the mix shift has further to run, so the revenue decline has further to run.

Quantifying the Rebate True-Up and the Price-Volume Wedge

A recurring line of questioning tried to strip the quarter back to trading by sizing the prior-period adjustments and then testing whether the residual price erosion had worsened. The first half of the question got a clean number. The second half, which put a specific price-mix figure to management, drew no correction and no number.

Q: "On U.S. injectable Wegovy®, you said there wasn't a shift in pricing dynamic between Q1 to Q2, but if you look at the gap between prescription growth and price, you had a negative price mix effect of about 57% up from about 40% in Q1. Is that just the cash pay mix that you're seeing?"
— Graham Parry, Citi

A: "In terms of Wegovy® injectable, you're going to see quarter-to-quarter fluctuation in terms of the price volume dynamics. I think, the mix in terms of channel mix reimbursed versus self-pay, as Karsten mentioned, is also impacting that."
— Jamey Millar, EVP US Operations

Assessment: A 17-point sequential worsening in the price-mix drag was put on the record and answered with the word "fluctuation." The gross-to-net disclosure that preceded it was genuinely good and specific; this was not. Realised price per script is the variable that converts the pill's volume triumph into a revenue outcome, and it remains the one number the company will not put on a slide.

Whether the Higher Oral Doses Should Be Repriced

With the pill's weekly script growth visibly decelerating and a wide gap between the two lower and two higher dose prices, the question was whether the price ladder itself is now the constraint. Management said no, and offered a subscription programme as the alternative to a list-price change.

Q: "Secondly, for Jamey, I guess ultimately, is it the right time to lower the price for higher doses of oral Wegovy? [...] Momentum seems to be stalling. What can you do about it?"
— Matthew Weston, UBS

A: "We have roughly 30% of prescriptions at the 9 and 25 milligram strength currently. Our preference would be to address consumer concerns about escalating prices as the product is titrated with this subscription model that we introduced just a couple of months ago. We've had good uptake of that. [...] We'll continue to use what I'll call more of a targeted surgical solution to that than a universal wholesale change to pricing."
— Jamey Millar, EVP US Operations

Assessment: Thirty percent of scripts at the two higher doses is the first real titration disclosure since launch and it answers a question that went unanswered in April. Thirty thousand subscription enrolments against roughly 2.9 million quarterly prescriptions is a very small instrument for the problem being described, which is why the phrase "targeted surgical" is doing the work. Note the framing has moved: in April the chief executive said the pill was priced correctly and volume proved it. Here the company is building mechanisms to soften the price step without changing the price, which is what a company does when the price is a problem it does not yet want to concede.

Whether 2027 Can Be a Growth Year

The central investor question in the name, asked directly and one quarter before formal guidance. The answer declined to commit and, in declining, listed the swing factors in the order management sees them.

Q: "A key investor debate is whether 2027 can mark a return to revenue growth, consensus currently flat-ish where I last checked. I realize Q2 numbers is not the forum for official guidance, but I think it's worth kicking the tires. I'm interested to gauge your level of comfort where consensus sits or your level of optimism about Novo returning to top-line growth in 2027, given all the various pushes and pulls."
— Peter Verdult, BNP Paribas

A: "We look forward to guide for 2027 come February next year. What I can say today, talking just in principles around it is, we're nicely positioned in a rapidly growing category. The GLP-1 market is growing close to 40%, when we look at moving annual totals. It's a fast-growing market with a long runway. That's, of course, a positive. We have laid out the recent dynamics. Actually, we did deliver 7% growth in the second quarter, so don't count us out there yet."
— Karsten Munk Knudsen, CFO

Assessment: "Don't count us out" is a sentiment, not a bridge, and citing the 7% quarter as evidence is citing a number that is three points of rebate true-up. The material omission is the January list-price reset, which was not mentioned in an answer about 2027 revenue despite being the single largest known variable in that year. Deferring the guide to February is entirely normal. Deferring the reset's quantification for a second consecutive quarter, in an answer specifically about 2027, is a choice.

What the Failed Cardiovascular Trial Says About the Inflammation Hypothesis

The most technically searching question of the call proposed that ZEUS had demonstrated inflammatory biomarkers to be correlates rather than causes, and asked what then justifies continued investment in the adjacent target. The response accepted the challenge, offered three alternative explanations, and pointed to a precedent trial in a different pathway.

Q: "My second question is on the implications of the ZEUS trial. Its failure amidst a reduction in CRP and IL-6 would seem to suggest that these inflammatory biomarkers are correlates of cardiovascular disease rather than causal factors. To what extent do you agree with that conclusion? In this context, what data serve as the basis for continued enthusiasm around NLRP3 in cardiometabolic disease?"
— Michael Nedelcovych, TD Cowen

A: "That can be caused by several reasons. Either there is no pharmacological correlate, or it was maybe a too diseased population that wasn't investigated. It could also be that IL-6 in this specific population is too far downstream in terms of the inflammation cascade, and NLRP3 are higher up. As you know, the CANTOS trial showed that IL-1 beta action introduced substantial CV benefits. I think it's too early to conclude that inflammation in CV should not be addressed."
— Martin Holst Lange, EVP Research and Development and Chief Scientific Officer

Assessment: A scientifically honest answer that does not oversell. Three candidate explanations for a null result is three explanations more than most managements offer, and the CANTOS reference is the right precedent. It changes nothing about the capital consequence: an asset with two continuing outcomes trials reading out in the first half of 2027 is now an option priced near zero, and the pipeline pillar that justified paying for optionality has one fewer leg.

What They're NOT Saying

1. Any quantification of the January 2027 list-price reset, for the second consecutive quarter. A roughly 50% reduction in wholesale acquisition cost on Wegovy and roughly 35% on Ozempic, effective on a known date, appears in the same one paragraph with the same one sentence on financial effect as in May. It drew no analyst question and management did not raise it in an answer explicitly about 2027 revenue. Net price impact, volume offset and gross-to-net mechanics all remain unpublished.
2. The realised price per prescription on the Wegovy pill. US pill sales of DKK 3,141M against around 2.9 million US prescriptions implies roughly DKK 1,083, or about USD 169, per script against a self-pay list of USD 149 to 299. The company disclosed both numbers and never put them together, and it separately warned that external data providers still under-capture pill prescriptions, which would push the implied figure lower still.
3. The Wegovy pill's gross margin. Now roughly 46% of US Wegovy scripts and the single largest driver of consolidated gross-margin trajectory. Unasked in April, unasked again here, and undisclosed.
4. Why free cash flow guidance implies a negative second half. First-half free cash flow of DKK 55.3bn against a full-year guide of DKK 45-55bn requires the remaining two quarters to consume cash. The raise was presented as good news, the arithmetic consequence was not presented at all, and no analyst asked.
5. A numerical sales and distribution ratio for the full year. In April the chief financial officer guided the ratio to the "low 20s" against Q1's 17.2%. The half has printed 18.2% and the disclosure now says only that promotional activities increase in the second half. Dropping the number makes the single largest swing factor in the second-half margin unverifiable.
6. The segment split of the DKK 6,328M impairment. Only the monlunabant component of DKK 4.0bn is named. The unallocated DKK 2,328M is what turns a growing Rare disease segment into a reported operating loss, and its absence makes the reported segment margins in this quarter as uninformative as the 340B-inflated ones in Q1.
7. Stay time, persistence and refill rates on the pill. Flagged as missing in April and still missing. Titration got a real number this quarter, roughly 30% of scripts at the two higher doses, which is progress. Discontinuation and persistence, the metrics that determine whether five million prescriptions becomes a durable revenue base, got none.
8. The IQVIA capture rate for the pill. Asked directly and not answered. The company states that external providers will "gradually improve their capture rate" over coming quarters, which is an argument for its own scripts being understated, and then declines to say by how much. That figure would settle whether the recent weekly script deceleration is real or an artefact.
9. Any commercial framing for CagriSema, one quarter before a US decision. A regulatory decision is expected at the end of 2026 with a potential 2027 launch, and the call covered trial mechanics only. Nothing on pricing, on positioning against a Wegovy portfolio that now has three products in the bag, or on what a missed HbA1c endpoint against the category leader does to the diabetes opportunity.

Market Reaction

• Pre-print setup: The ADR closed at $47.09 on 3 August, down 7.4% year to date against the S&P 500's +11.0%, down 3.5% over the trailing twelve months and down 6.6% over the trailing thirty days from $50.43 on 2 July. The 52-week closing range entering the print was $35.29 to $63.98. Two sessions earlier the stock had closed at $51.61.
• The ZEUS session: On 31 July, following the ziltivekimab readout, the ADR fell 8.8% to $47.08 on 26.8 million shares against a normal ten to eleven million, while the S&P 500 rose 0.7%. The stock went into the print having already surrendered its July gains.
• Reaction session (4 August, before-the-open reporter): Opened at $47.59, a 1.1% gap up, traded a range of $43.68 to $49.15, and closed at $44.28, down 6.0% or $2.81. The S&P 500 rose 1.8% the same session, so the relative move on a 16% operating-profit beat and a six-point guidance raise was roughly negative eight percentage points.
• Volume: 47.5 million ADRs against a 10.8 million thirty-day average, or 4.4x normal.
• Two-session context: Across 31 July and 4 August the ADR fell 14.2%, from $51.61 to $44.28, while the S&P 500 rose 4.0%.

The intraday path is the tell. The stock gapped up on the headline, traded as high as $49.15, and then spent the session giving back 9.9% from that high to close near the low. That is not a market disagreeing with the guidance raise; it is a market reading the disclosure in sequence and finding three things the headline did not carry.

What the tape worked out during the session. First, the flagship US product declined 22% at constant currency, a figure that appears in the regional appendix rather than the highlights. Second, the second-half guide implied by the same raise that led the wires is a mid-single-digit to low-double-digit decline, and the chief financial officer's own bridge, DKK 5bn of non-repeating gross-to-net plus back-end-loaded loss of exclusivity, arrived thirty minutes into the call. Third, the pill line missed its polled figure, narrowly, and on the one line where the market had granted the company the benefit of the doubt all year. Each of those lands after the headline rather than with it, and each of them argues that the raise is a first-half true-up rather than a change in trajectory.

Positioning context. A stock that has already fallen 8.8% on a failed phase 3 two sessions earlier is not carrying euphoric positioning into a print, so the sell-off is not a valuation unwind. What it looks like instead is a re-underwriting: the ZEUS session removed a pipeline leg, and this session removed the assumption that the US obesity franchise would inflect on the pill. Both were components of the same bull case, and they were repriced two trading days apart. Against a twelve-month move of only -3.5%, the market has spent a year deciding this business is worth roughly what it was worth, while the composition of the argument underneath has changed substantially.

Street Perspective

Debate: Is the Guidance Raise a Change in Trajectory or a Cash-In of the First Half?

Bull view: Six points on both ends with the band narrowing from eight to six is a different action from May's one-point parallel shift, and it is the second raise in six months. Free cash flow guidance rose DKK 9bn. A management team that has beaten and raised twice, on delivered rather than expected results, is a team whose forecasting can now be trusted, and the market is applying a credibility discount that the evidence no longer supports.

Bear view: The raise upgrades a half that is already banked. The implied second half is roughly -7.5% at constant currency against a first half of +2%, and management named the two reasons without being pressed. Three points of the quarter's 7% growth is a prior-period rebate true-up, and the guidance still describes a shrinking business in its best-case scenario. A company whose ceiling is zero growth is not being discounted, it is being valued.

Our take: The bull framing is right about the action and the bear framing is right about the content. This is the first Novo guidance revision that carries genuine information, and what it informs you of is that the low case has been retired rather than that the trajectory has improved. Both can be true, and together they justify a higher price than the pre-ZEUS multiple implied but not a re-rating. Note also that a full-year ceiling of 0% growth, set after a first half of +2%, is management telling you the second half is worse and doing so in the same sentence as the good news.

Debate: Does the Pill's Global Rollout Fix the Revenue Problem or Export It?

Bull view: Three hundred thousand UK patient starts in three weeks, against a national treated base of 1.6 million and a 20 million addressable population, is the clearest evidence yet that the oral formulation expands markets rather than dividing them. Novo's UK obesity share went from roughly 30% to 45% in a month. Around 80% of pill users are treatment-naive, the product holds roughly 90% of the US oral segment against a competitor that launched in April, and the same playbook now runs in Germany from September.

Bear view: Every one of those patients is being acquired at an oral price point, and the US quarter shows what that does to a revenue line: injectable Wegovy down 22% at constant currency with self-pay at 35% of the franchise, total US obesity revenue up 4% into an 87% volume market. The international rollout is therefore the mechanism by which the lower realised price propagates worldwide, and it is arriving before the volume base is large enough to compensate.

Our take: The bear case has the better of the mechanism for a second consecutive quarter, and the US numbers are now the proof rather than the prediction. But the UK datapoint is materially stronger than anything in the Q1 evidence set, because a nineteen percent expansion of a country's treated population in three weeks is elasticity of a different order from what US self-pay pricing produced. The honest position is that the race between volume and price has not been settled, that Novo is losing it in the US today, and that the UK is the first market where it might not.

Debate: Has the Pipeline Optionality Argument Survived the Quarter?

Bull view: One trial in one high-risk mechanism failed, and management said at the outset that ziltivekimab carried roughly even odds. Two further outcomes trials in the same molecule read out in the first half of 2027. CagriSema still has a US obesity decision at year-end, the lower-dose REDEFINE 9 trial succeeded, a high-dose phase 3 has started, and etavopivat files in both the US and EU this quarter. The next-generation combination programme entered phase 3 with an additional titration step built from the CagriSema experience. This is a broad pipeline having a bad quarter, not a broken one.

Bear view: In ninety days the company wrote off an obesity asset, watched its cardiovascular programme return a hazard ratio of 0.99 on both the primary endpoint and all-cause mortality, and failed half of a dual primary endpoint against the category leader with its designated semaglutide successor. That successor has now disappointed twice in eighteen months. The optionality being paid for is optionality on assets that keep failing to differentiate.

Our take: The bear case is closer to right, and it is a change from April when we scored pipeline optionality as confirmed on a genuinely productive quarter. The distinction that matters is between attrition and pattern. One failed high-risk mechanism is attrition. A failed mechanism plus a terminated asset plus a second consecutive disappointment on the lead successor compound, and they compound into the same 2027 and 2028 window in which semaglutide exclusivity unwinds and the list price resets. The September capital markets day is where this either gets reframed or hardens into the bear case.

Model Update & Valuation Framework

Changes to the assumptions we opened with in May, driven by the guidance revision and the first half's actuals.

A note on the 2025 earnings base. The adjusted net profit definition changed for 2026 to also exclude 340B provision reversals, major legal matters and major impairments on property, plant and equipment. The FY2025 adjusted diluted EPS of DKK 26.17 that the company printed in February is on the old definition. Restated to the current one, it is DKK 25.70, because the Q2 2025 340B reversal is now stripped out. The company itself restated the first half of 2025 from DKK 13.18 to DKK 12.71 on exactly that basis. Using DKK 26.17 as the growth base overstates 2026 earnings by roughly 2%.

Valuation framework. Starting from FY2025 adjusted diluted EPS restated to the current definition of DKK 25.70, applying the guided adjusted operating profit range translated into kroner (0% to -6% at constant currency, around two points lower as reported, so -2% to -8%), then deducting roughly DKK 0.70 per share for the guided deterioration in financial items and holding the tax rate and share count flat, gives 2026 adjusted EPS of roughly DKK 22.9 to 24.5, with a midpoint near DKK 23.7. Building the same estimate from the halves, the first half's actual DKK 12.81 plus a second half discounted for both the operating decline and the financial-items swing, lands at DKK 23.1 to 23.8 and puts the working number in the lower part of the range. At the company's own stated spot rate of 6.51 kroner to the dollar, DKK 23.7 is approximately $3.64 per ADR.

Against the $44.28 reaction close, the ADR therefore trades at approximately 12.2x our 2026 midpoint, against 13.9x on our May estimate of $3.30. The stock is cheaper on a higher number, which is the arithmetic result of a six-point guidance raise being met with a six percent decline.

Fair value range: $44 to $55, midpoint $49. The range applies 12x to 15x to the 2026 midpoint estimate. The low end implies -0.6% from the $44.28 close, the midpoint implies +10.7%, and the high end implies +24.2%. We have widened the range rather than narrowed it despite the guidance de-risking, because the two developments that would justify a multiple above 15x, evidence that 2027 earnings grow through the January list-price reset and evidence that the US obesity franchise participates in its market's volume growth, both moved further away this quarter rather than closer. A multiple below 12x requires believing the franchise is impaired rather than repriced, and 2.9 million quarterly pill prescriptions with 300,000 UK starts in three weeks contradicts that.

Thesis Scorecard Post-Earnings

The pillars below are the standing thesis established at initiation in May, graded against this quarter's print and call. They are unchanged in wording; only the status and the notes move.

Overall: Unchanged in net, with more movement underneath than the net suggests. Four tags moved: the cost pillar strengthened, the efficacy-parity and pipeline pillars weakened, and the loss-of-exclusivity pillar moved from contained to emerging. The two bear pillars that decide the revenue line were confirmed again, and the US one strengthened. The quarter's genuine achievements, a six-point guidance raise with a narrowed band, an operating margin up 100bps despite a one-time charge, and the best international launch in the company's recent history, all sit on one side of a ledger whose other side is a 22% decline in the flagship US product and a pipeline that lost an asset and a mechanism in ninety days.

Action: Hold. At approximately 12.2x our 2026 adjusted earnings estimate the ADR is cheaper than it was in May on a higher estimate, and the guidance floor has moved seven points since February, which rules out Underperform. The two conditions we named at initiation for moving toward Outperform were a narrowing of the gap between US obesity revenue growth and US market volume growth, and a quantified 2027 bridge across the January list-price reset. The first went backwards and the second was deferred to February. We would revisit toward Outperform if US obesity revenue growth reaccelerates while the branded market's volume growth decelerates toward it, or if the September capital markets day produces a quantified 2027 price-and-volume bridge. We would revisit toward Underperform if the UK and Germany launches settle into the same volume-up, revenue-down pattern the US has established, or if the second half misses a guidance floor that management has now explicitly de-risked.